Allogene Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Allogene Therapeutics es David Chang , nombrado en Jun 2018, tiene una permanencia de 6.42 años. compensación anual total es $14.06M, compuesta por 5.1% salario y 94.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.68% de las acciones de la empresa, por valor de $17.07M. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 6.6 años, respectivamente.
Información clave
David Chang
Chief Executive Officer (CEO)
US$14.1m
Compensación total
| Porcentaje del salario del CEO | 5.1% |
| Permanencia del CEO | 6.4yrs |
| Participación del CEO | 3.7% |
| Permanencia media de la dirección | 1.7yrs |
| Promedio de permanencia en la Junta Directiva | 6.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Nov 22
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Aug 27Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Jun 12We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
May 30Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$283m |
| Jun 30 2024 | n/a | n/a | -US$279m |
| Mar 31 2024 | n/a | n/a | -US$292m |
| Dec 31 2023 | US$14m | US$724k | -US$327m |
| Sep 30 2023 | n/a | n/a | -US$344m |
| Jun 30 2023 | n/a | n/a | -US$365m |
| Mar 31 2023 | n/a | n/a | -US$361m |
| Dec 31 2022 | US$15m | US$724k | -US$340m |
| Sep 30 2022 | n/a | n/a | -US$313m |
| Jun 30 2022 | n/a | n/a | -US$308m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$10m | US$695k | -US$182m |
| Sep 30 2021 | n/a | n/a | -US$251m |
| Jun 30 2021 | n/a | n/a | -US$239m |
| Mar 31 2021 | n/a | n/a | -US$229m |
| Dec 31 2020 | US$8m | US$675k | -US$316m |
| Sep 30 2020 | n/a | n/a | -US$243m |
| Jun 30 2020 | n/a | n/a | -US$227m |
| Mar 31 2020 | n/a | n/a | -US$207m |
| Dec 31 2019 | US$11m | US$600k | -US$185m |
| Sep 30 2019 | n/a | n/a | -US$154m |
| Jun 30 2019 | n/a | n/a | -US$147m |
| Mar 31 2019 | n/a | n/a | -US$240m |
| Dec 31 2018 | US$13m | US$362k | -US$212m |
Compensación vs. Mercado: La compensación total de David($USD14.06M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.14M).
Compensación vs. Ingresos: La compensación de David ha sido consistente con los resultados de la empresa en el último año.
CEO
David Chang (64 yo)
6.4yrs
Permanencia
US$14,061,848
Compensación
Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Director of Allogene Therapeutics, Inc since June 2018. He served as Chief Medical Officer and Executive Vice President of Rese...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 7yrs | US$9.36m | 2.92% $ 13.5m | |
| Co-Founder | 6.4yrs | US$14.06m | 3.68% $ 17.1m | |
| Co-Founder & Director | no data | US$684.49k | 0.14% $ 669.8k | |
| Executive VP & Chief Technical Officer | 1.6yrs | US$5.80m | 0.13% $ 586.7k | |
| Executive VP of Research & Development and Chief Medical Officer | 1.8yrs | US$8.13m | 0.018% $ 84.6k | |
| Executive VP & CFO | 1.1yrs | sin datos | 0.54% $ 2.5m | |
| Senior VP | less than a year | sin datos | sin datos | |
| Senior VP | 1.3yrs | sin datos | 0.21% $ 993.0k | |
| Chief People Officer | 2.5yrs | sin datos | sin datos | |
| Executive VP | 1.8yrs | sin datos | sin datos | |
| Senior Vice President of Finance | no data | sin datos | 0.042% $ 196.4k | |
| Secretary | no data | sin datos | sin datos |
1.7yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALLO no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 7yrs | US$9.36m | 2.92% $ 13.5m | |
| Co-Founder | 6.4yrs | US$14.06m | 3.68% $ 17.1m | |
| Co-Founder & Director | 7yrs | US$684.49k | 0.14% $ 669.8k | |
| Lead Independent Director | 6.6yrs | sin datos | sin datos | |
| Independent Director | 6.6yrs | US$585.00k | 0.15% $ 700.0k | |
| Independent Director | 6.6yrs | US$510.00k | 0.12% $ 564.8k | |
| Independent Director | 6.6yrs | sin datos | sin datos | |
| Independent Director | 6.2yrs | US$495.00k | 0.080% $ 368.6k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6.6yrs | sin datos | sin datos |
6.6yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: La junta directiva de ALLO se considera experimentada (6.6 años de antigüedad promedio).